Cargando…
Long-term outcome of bioresorbable vascular scaffolds for the treatment of coronary artery disease: a meta-analysis of RCTs
BACKGROUND: Coronary bioresorbable scaffolds (BRS) were developed to overcome the limitations of standard metallic stents, especially to address late events after percutaneous coronary interventions. The aim of this meta-analysis was to evaluate the efficacy and safety of BRS, compared with Everolim...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5463321/ https://www.ncbi.nlm.nih.gov/pubmed/28592227 http://dx.doi.org/10.1186/s12872-017-0586-2 |
_version_ | 1783242682078855168 |
---|---|
author | Polimeni, Alberto Anadol, Remzi Münzel, Thomas Indolfi, Ciro De Rosa, Salvatore Gori, Tommaso |
author_facet | Polimeni, Alberto Anadol, Remzi Münzel, Thomas Indolfi, Ciro De Rosa, Salvatore Gori, Tommaso |
author_sort | Polimeni, Alberto |
collection | PubMed |
description | BACKGROUND: Coronary bioresorbable scaffolds (BRS) were developed to overcome the limitations of standard metallic stents, especially to address late events after percutaneous coronary interventions. The aim of this meta-analysis was to evaluate the efficacy and safety of BRS, compared with Everolimus-eluting stents (EES), using the data available from randomized trials, with a focus on long-term outcomes. METHODS: Published randomized trials comparing BRS to EES for the treatment of coronary artery disease were searched for within PubMed, Cochrane Library and Scopus electronic databases up to April 4th 2017. The summary measure used was odds ratio (OR) with 95% confidence intervals. RESULTS: A total of 5 studies were eligible, including 5219 patients. At 2 years, BRS was associated with higher rates of target lesion failure (9.4% vs 7.2%; OR = 1.33; 95% CI 1.07 to 1.63; p = 0.008) and device thrombosis (2.3% vs 0.7%; OR = 3.22; 95% CI 1.86 to 5.57; p < 0.0001) compared with EES. The incidence of both early (within 30 days after implantation, 1.1% vs 0.5%, OR 1.97, 95% CI 1.02 to 3.81; p = 0.05) and very-late device thrombosis (>1 year, 0.6% vs 0.1%, OR 4.03, 95% CI 1.37 to 11.82; p = 0.01) was higher with BRS compared with EES. CONCLUSIONS: BRS may be associated with worse two-years clinical outcomes compared with EES in patients with coronary artery disease. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12872-017-0586-2) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-5463321 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-54633212017-06-08 Long-term outcome of bioresorbable vascular scaffolds for the treatment of coronary artery disease: a meta-analysis of RCTs Polimeni, Alberto Anadol, Remzi Münzel, Thomas Indolfi, Ciro De Rosa, Salvatore Gori, Tommaso BMC Cardiovasc Disord Research Article BACKGROUND: Coronary bioresorbable scaffolds (BRS) were developed to overcome the limitations of standard metallic stents, especially to address late events after percutaneous coronary interventions. The aim of this meta-analysis was to evaluate the efficacy and safety of BRS, compared with Everolimus-eluting stents (EES), using the data available from randomized trials, with a focus on long-term outcomes. METHODS: Published randomized trials comparing BRS to EES for the treatment of coronary artery disease were searched for within PubMed, Cochrane Library and Scopus electronic databases up to April 4th 2017. The summary measure used was odds ratio (OR) with 95% confidence intervals. RESULTS: A total of 5 studies were eligible, including 5219 patients. At 2 years, BRS was associated with higher rates of target lesion failure (9.4% vs 7.2%; OR = 1.33; 95% CI 1.07 to 1.63; p = 0.008) and device thrombosis (2.3% vs 0.7%; OR = 3.22; 95% CI 1.86 to 5.57; p < 0.0001) compared with EES. The incidence of both early (within 30 days after implantation, 1.1% vs 0.5%, OR 1.97, 95% CI 1.02 to 3.81; p = 0.05) and very-late device thrombosis (>1 year, 0.6% vs 0.1%, OR 4.03, 95% CI 1.37 to 11.82; p = 0.01) was higher with BRS compared with EES. CONCLUSIONS: BRS may be associated with worse two-years clinical outcomes compared with EES in patients with coronary artery disease. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12872-017-0586-2) contains supplementary material, which is available to authorized users. BioMed Central 2017-06-07 /pmc/articles/PMC5463321/ /pubmed/28592227 http://dx.doi.org/10.1186/s12872-017-0586-2 Text en © The Author(s). 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Article Polimeni, Alberto Anadol, Remzi Münzel, Thomas Indolfi, Ciro De Rosa, Salvatore Gori, Tommaso Long-term outcome of bioresorbable vascular scaffolds for the treatment of coronary artery disease: a meta-analysis of RCTs |
title | Long-term outcome of bioresorbable vascular scaffolds for the treatment of coronary artery disease: a meta-analysis of RCTs |
title_full | Long-term outcome of bioresorbable vascular scaffolds for the treatment of coronary artery disease: a meta-analysis of RCTs |
title_fullStr | Long-term outcome of bioresorbable vascular scaffolds for the treatment of coronary artery disease: a meta-analysis of RCTs |
title_full_unstemmed | Long-term outcome of bioresorbable vascular scaffolds for the treatment of coronary artery disease: a meta-analysis of RCTs |
title_short | Long-term outcome of bioresorbable vascular scaffolds for the treatment of coronary artery disease: a meta-analysis of RCTs |
title_sort | long-term outcome of bioresorbable vascular scaffolds for the treatment of coronary artery disease: a meta-analysis of rcts |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5463321/ https://www.ncbi.nlm.nih.gov/pubmed/28592227 http://dx.doi.org/10.1186/s12872-017-0586-2 |
work_keys_str_mv | AT polimenialberto longtermoutcomeofbioresorbablevascularscaffoldsforthetreatmentofcoronaryarterydiseaseametaanalysisofrcts AT anadolremzi longtermoutcomeofbioresorbablevascularscaffoldsforthetreatmentofcoronaryarterydiseaseametaanalysisofrcts AT munzelthomas longtermoutcomeofbioresorbablevascularscaffoldsforthetreatmentofcoronaryarterydiseaseametaanalysisofrcts AT indolficiro longtermoutcomeofbioresorbablevascularscaffoldsforthetreatmentofcoronaryarterydiseaseametaanalysisofrcts AT derosasalvatore longtermoutcomeofbioresorbablevascularscaffoldsforthetreatmentofcoronaryarterydiseaseametaanalysisofrcts AT goritommaso longtermoutcomeofbioresorbablevascularscaffoldsforthetreatmentofcoronaryarterydiseaseametaanalysisofrcts |